Navigation Links
InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
Date:9/16/2008

- Biotech Begins to Demonstrate Strategy to Expand NHL Marketplace with Novel Antibody and Speedy DXL Screening Preclinical Development Program -

BRITISH COLUMBIA, Canada, Sept. 16 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced today the results of an extensive mouse tumor study demonstrating superiority of InNexus' DXL625 (CD20) versus Rituxan(R) in the xenograft model.

InNexus plans to submit the data for publication along with additional data from animal studies recently completed and presented at the American Association for Cancer Research (AACR) 2008 Annual Conference. The company has also launched a large scale study of DXL625 with primates, designed to evaluate toxicity and pharmokinetics, enabling the company to move the product to the FDA toward human testing.

"A study performed by an independent group investigating the survival of mice intravenously injected with B-lymphoma cells and treated subsequently with DXL625 showed a significant improvement in outcome compared to animals treated with equivalent doses of Rituxan(R), a commercially available anti-CD20 antibody," said Dr. Thomas Kindt, InNexus' Chief Scientific Officer. "Animals treated with either drug had a superior outcome when compared to those receiving inactive control (vehicle), however DXL625 had a substantial advantage over the competing antibody. We are confident that these results will translate to therapeutic advantage when DXL625 is used in human subjects."

"The DXL(TM) technology platform builds better antibodies and soon you'll be able to see our strategy to expand the NHL marketplace. We enhance an antibody's potency in a real, measurable and predictable fashion," said Jeff Morhet, Chairman and Chief Executive Officer. "I'm pleased with our scientific progress, regulatory plans and soon we'll be well positioned to begin formal discussions with the FDA."

About DXL(TM) Technology Platform

DXL(TM) technology works by integrating self-binding peptides into monoclonal antibodies, potentiating target binding. Modified antibodies "cluster" upon engaging the target receptor site, resulting in greater "molecular mass" at the point of association. DXL(TM) antibodies have significantly extended dissociation rates, as measured by surface plasmon resonance. As a consequence, this may facilitate cancer cell destruction in a target dependent manner by increasing apoptosis, antibody dependent cell cytotoxicity and complement-dependent cytotoxicity. To learn more about InNexus' DXL(TM) technology, please visit http://www.ixsbio.com.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of new and existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in- house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 2017  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. ... of directors: Christopher Gabrieli ... serve as chairman of the board of Akcea Therapeutics. ... of Forest Laboratories. Sandford D. Smith ... "We are excited to announce this expansion to ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... market  is expected to reach a value of USD ... by Grand View Research, Inc. Proper closure of injured ... tissue,s structure and function. Postoperative leakages occur in 3% ... serious complication. They are responsible for one third of ...
(Date:3/27/2017)... The National University of Singapore (NUS) ... company, signed a Memorandum of Understanding (MOU) recently ... the region. Under this MOU, ... Technology (BIGHEART) at NUS and Holmusk will establish ... healthcare IT and medical device development. These include ...
Breaking Medicine Technology:
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
(Date:3/28/2017)... Petersburg Florida (PRWEB) , ... March 28, 2017 , ... ... Marine Corp to raise money to for the Toys for Tots Literacy Campaign at ... federal budget in excess of $70 billion, the U.S. ranks at number 14 internationally ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to earn placements ... channels. , While many results are clear, much of PR is hard to quantify. ... it comes to measurement, firms should always take an all-inclusive approach that takes both ...
(Date:3/28/2017)... ... , ... Thank you to all who attended Capio Partners Winter 2017 Healthcare ... exclusive to providers and offered an opportunity to collaborate and network with healthcare colleagues ... Hyatt where attendees gathered for a lively discussion on trends and issues that healthcare ...
(Date:3/27/2017)... ... March 27, 2017 , ... The respected dental team at ... teeth without the extensive time commitment and aesthetic disadvantages of traditional braces can ... A custom-designed series of virtually invisible aligners are created for each patient and ...
Breaking Medicine News(10 mins):